Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
histamine-added human immunoglobulin
- Development stage
- Phase 4
- Lead developer
- KM Biologics
- Administration
- Subcutaneous
01
Overview
Histaglobin is a biologic combination of human normal immunoglobulin (IgG) and histamine dihydrochloride, primarily developed by KM Biologics (formerly Kaketsuken) for the treatment of various allergic and respiratory conditions. Administered via subcutaneous injection, it works through a unique mechanism known as histaminopexy, where it stimulates the production of antibodies against the histamine-immunoglobulin complex. These antibodies neutralize free histamine released during allergic reactions, preventing it from binding to its receptors and triggering symptoms. Additionally, Histaglobin has been shown to modulate the Th1/Th2 immune balance toward a Th1-favoring profile, inhibit NF-kappaB activation, and reduce the release of pro-inflammatory cytokines such as IL-1β, TNF-α, and IL-6. It is indicated for the treatment of bronchial asthma, allergic rhinitis, vasomotor rhinitis, chronic urticaria, and atopic dermatitis.
- Brand names
- HistaglobinHistaglobulinHistobulinHistoglob
- Other names
- Histaglobin S.C. InjectionHistamine-fixed immunoglobulinImmunoglobulin/histamine complexIHCHistamine-human immunoglobulin complex
02
Targets
HRH1 (Histamine H1 Receptor)HRH2 (Histamine H2 Receptor)HRH3 (Histamine Receptor H3)HRH4 (Histamine H4 receptor)
Beyond the preview
Go deeper on histamine-added human immunoglobulin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on histamine-added human immunoglobulin.